Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

Large Outcome Studies Reported at AAOS Annual Meeting Support Longterm

Clinical Duration

CAMBRIDGE, Mass., March 10 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ), today announced findings from a large, multicenter, observational study that investigated the long-term durability of Carticel(R) (autologous cultured chondrocytes) in patients who had pain and functional impairment from defects in the articular cartilage of their knee. These findings revealed that almost 90 percent of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost 10 years. The data were presented at this week's American Academy of Orthopaedic Surgeons' (AAOS) annual meeting in San Fransisco.

"We knew that autologous chondrocyte implantation (ACI) worked for select patients, but did it last?" said Allen Anderson, MD, (Nashville, TN) a leading orthopaedic surgeon in the field of sports medicine who presented the data at the medical meeting. "These data suggest that the ACI technique not only works, but when it works, the results will last for a long time. Similar results of long term durability had been previously reported by Lars Peterson, M.D., but this multicenter experience suggests that sustainable results can be reproduced by others."

Study Results

The objectives of the study were to determine if a patient's improvement assessed at an early timepoint, defined as 1 to 5 years (mean 4.6 years) after Carticel implantation, could be sustained at a much later time point defined as 6 to 10 years (mean 9.2 years).

Seventy-two patients were enrolled from 35 different centers across the US. All patients enrolled h
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Wrightington, Wigan and Leigh ... MDRX ) are delighted to announce WWL,s decision to ... information system. The system will be implemented across all ... WWL delivers healthcare in the future. ... on-time and on-budget system implementations as well as its ...
(Date:9/30/2014)... 30, 2014 STUDY OBJECTIVES The ... to provide an overview of the current and ... drugs/therapeutics. The key objective is to present a ... as an important tool in the treatment of ... future strategies within the protein therapeutics market, which ...
(Date:9/30/2014)... 30, 2014  According to their CEO, ... clinical trials is going through a complete transformation ... work of the current clinical trial management process ... generation, clinical trials, which will ultimately drive the ... The company has been recognized by the National ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Calif., May 3, 2012 Alarm bells are ringing ... proportions worldwide, triggering intensive ophthalmic research into vision-compromising comorbidities. ... diabetic retinopathy will triple from 5.5 million in 2005 ... leading cause of blindness in working age people, improved ...
... Dutch Medical Brands receives first European ... traditional treatment with antibiotics, bladder and urinary tract infections ... effects. Dutch company Medical Brands has obtained a Class ... making it the first and only cranberry-based product in ...
Cached Medicine Technology:Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant 2Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant 3Cranberry Capsule Proven to Cure Bladder Infection 2
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... Bedros Keuilian is not only the founder ... camps, he’s also considered the leading expert on marketing ... business summits, a line of high-demand fitness marketing systems ... Spike TV reality show to his name. , With ... for personal trainers and fitness business owners to focus ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... News) -- Elevated blood levels of a central nervous system ... by a lack of oxygen, according to a new study. ... can also help doctors assess the effectiveness of a body-cooling ... Johns Hopkins researchers said. GFAP is specific to central ...
... HealthDay Reporter , THURSDAY, Oct. 13 (HealthDay News) ... epilepsy remain free of seizures 10 years later, a new ... medication, and only when drugs can,t control seizures -- often ... for surgery. This study suggests that some patients with focal ...
... procedure that measures the amount of oxygen in the ... detect critical congenital heart disease (CCHD) in infants, and ... standard for CCHD diagnosis, according to a new research ... of Pediatrics (AAP) National Conference and Exhibition (NCE) in ...
... THURSDAY, Oct. 13 (HealthDay News) -- Smoky, inefficient indoor cooking ... developing nations contribute to 2 million deaths a year, according ... affects about 3 billion people, or nearly half the world,s ... in a commentary published in the current issue of the ...
... CHAMPAIGN, Ill. What if you could trace the history of ... camera, you could learn what factory made the ingredients in your ... or even how to recycle the phone. You could follow the ... along the way to ensure that the medicine you,re taking isn,t ...
... 13 (HealthDay News) -- Nearly one in four Americans with ... undiagnosed psoriatic arthritis, according to a new study. This ... United States who have been diagnosed with the disease, a ... and can lead to joint destruction and disability. For ...
Cached Medicine News:Health News:Protein May Help Spot Newborns With Brain Damage 2Health News:For Many, Epilepsy Surgery Effective Long-Term 2Health News:For Many, Epilepsy Surgery Effective Long-Term 3Health News:Globally, 2 Million Deaths a Year Linked to Smoky Stoves 2Health News:Packaging expert sees a social revolution in the evolving barcode 2Health News:Packaging expert sees a social revolution in the evolving barcode 3Health News:1 in 4 With Psoriasis May Have Undiagnosed Arthritis 2
... a 28 amino-acid lipophilic peptide with a ... serine residue three, that is primarily expressed ... the mucosa of the fundus of the ... to those of leptin. Ghrelin stimulates food ...
... The Medtronic SelectSecure Lead System (Model 3830) ... Its unique, lumenless design allows for flexibility ... without sacrificing insulation thickness. The SelectSecure lead ... positioning of the lead in select locations ...
... Human sex hormone-binding globulin (SHBG) is ... steroids with relatively high specificity and low ... bound to SHBG) and, to a much ... C18 and C19 steroid structures and regulates ...
... is the glucuronide conjugate of 3alpha-androstanediol, ... [1,2]. 3alpha-diol G has strong androgenic ... bioactivity of testosterone [2]. Serum 3alpha-diol ... reduction of DHT, and in addition, ...
Medicine Products: